Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sunshine Biopharma Inc. - Warrant (NQ: SBFMW )

0.1158 UNCHANGED
Streaming Delayed Price Updated: 3:55 PM EDT, Oct 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sunshine Biopharma Inc. - Warrant

Sunshine Biopharma Q2 Report Reveals Approximately 1,940% Increase In Cash & Cash Equivalents And 80% Decrease In Net Loss Within 6 Months
Sunshine Biopharma, Inc. (NASDAQ: SBFM) (NASDAQ: SBFMW) announced that it has filed its 2022 second-quarter report with the Securities and Exchange Commission. 
Via Benzinga
Sunshine Biopharma Reveals Potential Intellectual Property Position In Connection With Ongoing mRNA-As-Therapeutics-Agents Research
Photo credit: Patent application by Nick Youngson CC BY-SA 3.0 
Via Benzinga
Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells
Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma, Inc. 
Via Benzinga
Sunshine Biopharma Sees Potential Multi-Billion Dollar Global Market Opportunity As Research Findings Reveal Effectiveness Against Multidrug-Resistant Cancer Cells
Photo by Angiola Harry on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. 
Via Benzinga
Sunshine Biopharma, Inc. Announces Pricing of $8 Million Private Placement Priced At-the-Market
Photo by Scott Graham on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.... 
Via Benzinga
Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ: SBFM; SBFMW)
NEW YORK, NY / ACCESSWIRE / February 17, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ:SBFM; SBFMW)... 
From Aegis Capital Corp.
Via AccessWire
Exposures COVID-19
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.